AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02528513 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Procedure:Weaning
Description: the respiratory therapists managed patients with a daily interruption of continuous sedation and the spontaneous breathing trial (SBT) protocols daily.
Study NCT04154384 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Clinical Coordination with Referrals
Description: The Life Care Specialist (LCS) can help arrange a referral for the participant, should a medical or social issue be identified during LCS intervention, including mental health services, addiction medicine services, housing insecurity referrals, food insecurity referrals, and amputee support. When giving referrals, the LCS works closely with physicians and nurses to make sure that the participant is a good fit for the referral program.
Study NCT04154384 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Pilot Study of Pain Management Strategies
Description: Orthopedic trauma patients will work with a Life Care Specialist (LCS) and will receive personalized pain management strategies to avoid potential opioid misuse.
Study NCT01136876 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Iopamidol
Description: Iopamidol 370, one time administration for percutaneous coronary intervention
Study NCT02528513 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: midazolam(used for passing the SBT safety screen)
Description: After the spontaneous breathing trial safety screen is passed,in the midazolam group, midazolam will continue to be used for sedation, with the dosage adjusted to RASS score (-2 to 0).
Study NCT02951442 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Biological sample
Study NCT02951442 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Non invasive Arterial investigations
Study NCT02951442 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Abdominal tomodensitometry
Study NCT01440036 — intervention group
Intervention type: PROCEDURE
Intervention: Carotid endarterectomy
Description: The removal of atherosclerotic plaque from the carotid artery, by surgery
Study NCT03653117 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transperineal laser ablation
Description: Minimal invasive coagulation of prostatic tissue by laser
Study NCT02854111 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ice cream
Description: The ice cream was made by nutritionists in Ramathibodi Hospital. It consisted of cornstarch, milk, sucrose, milk powder, egg yolk, and banana which contained carbohydrate 73.9 g, fat 27.7 g, protein 18.9 g for a total of 620.9 kcal with a cost of 35 bahts. The time for complete ingesting 75-g glucose and ice cream was 5 and 15 minutes, respectively.
Study NCT02854111 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: 75 g-glucose
Description: The 75-g glucose is used for standard oral glucose tolerance test.
Study NCT02102516 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SPRIX(intranasal ketorolac tromethamine)
Description: Dose: Subjects weighing 3.0 kg received 3.15 mg (1 spray/1 nostril), subjects weighing 5.1 - 10.0 kg received 5.25 mg (1 spray/1 nostril), subjects weighing 10.1 - 15.4 kg received 10.5 mg (1 spray/1 nostril), subjects weighing 15.5 - 31.7 kg received 15.75 mg (1 spray/1 nostril), and subjects weighing >=31.8 kg received 31.5 mg (1 spray/2 nostrils).~Duration of Treatment: Subjects received a dose of SPRIX every 6 hours from the day of surgery until the morning of post-operative Day 2. Dosing may have resumed after final PK assessment of the morning of post-operative Day 3 until post-operative Day 4. A follow-up phone interview took place 14 days after the final dose of study drug.
Study NCT02939833 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Scalp Nerve Blocks With Ropivacaine
Study NCT02939833 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Scalp Nerve Blocks With Saline
Study NCT02603393 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: QVA149
Description: QVA149 will be supplied in a capsule form in blister packs for use in the Novartis Concept 1 SDDPI
Study NCT02603393 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tiotropium
Description: Tiotropium will be supplied as commercially available blisters, delivered via HandiHaler®
Study NCT02603393 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Salmeterol/fluticasone
Description: Salmeterol/fluticasone propionate dry inhalation powder delivered via Accuhaler™
Study NCT01136876 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Iodixanol-320
Description: Iodixanol-320 single administration for percutaneous coronary intervention procedure
Study NCT03396900 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: RhBMP-2 Protein, Recombinant
Description: Bone morphogenetic proteins (BMPs) are a category of proteins that are involved in bone formation and repair. Among these, BMP-2 is one of the most potent members of the BMP family and has been used for correcting intrabony, supraalveolar, furcation, and fenestration defects due to its osteoinductive property. BMP's are also essential for differentiation of osteoclasts, but their role in this process remains unclear. Treatment of osteoclasts with exogenous BMP-2 directly enhances RANKL-stimulated differentiation of osteoclast precursors in vitro and stimulates survival and resorptive activity of mature osteoclasts that accelerates the tooth movement.
Study NCT03396900 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Conventional Corticotomy
Description: A conventional PAOO Surgical procedure will be performed for individuals in this arm
Study NCT00854191 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: simulator training
Description: 4 half-day of simulator ERCP practice as endoscopist and/or assistant followed by usual training
Study NCT00854191 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: simulator training
Description: 4 half-day of simulator ERCP practice as endoscopist and/or assistant followed by usual training
Study NCT00533546 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Activated Protein C
Description: Intravenous APC (10, 15, 22, 33, 50, and 75 mcg/kg) administered to patients with acute ischemic stroke within 0 - 9 hours of symptom onset
Study NCT02755415 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: HIWIN Robotic Gait Training System
Description: HIWIN Robotic Gait Training System is an automatic training system that combines weight-bearing standing, repetitive stepping and gait training
Study NCT02755415 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Static Standing Table
Description: As part of the standard hospital rehabilitation, static standing table allows patient to be in a fully supported standing position
Study NCT02219568 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: CT enterography
Description: CT enterography is performed using 64-channel multi-detector row CT scanners (Siemens Sensation 64, Siemens Medical solution, Forchiem, Germany). Prior to the scan, 1500 cc of a neutral oral-enteric contrast material, polyethylene glycol (NIFLEC) is taken by the patient. During the scan, 2cc/kg of intravenous contrast (iohexol, Ominipaque Amersham GE-Health care, Princeton, NJ) is injected at the velocity 5 cc/sec.
Study NCT02219568 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: video capsule endoscopy
Description: Video capsule endoscopy is performed using PillCam SB (Given Imaging, Yokneam, Israel). Polyethylene glycol (NIFLEC) is used for bowel preparation.
Study NCT02879760 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ad-MAGEA3
Description: Intramuscular injection
Study NCT02879760 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MG1-MAGEA3
Description: Intravenous infusion
Study NCT02879760 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Intravenous infusion
Study NCT03569072 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Functionally adapted, dose escalated VMAT radiotherapy
Description: Volumetric Modulated Arc Therapy planning and treatment delivery to treat primary and nodal planning target volume with 60 Gy in 30 fractions and a simultaneous integrated boost to the primary tumour to a total dose 69Gy in 30 fractions while avoiding organs at risk including functional lung, heart and oesophagus.
Study NCT04277936 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levetiracetam 500 mg
Description: Levetiracetam (LEV) regulates neuronal synaptic exocytosis and calcium-induced neurotransmitter release and has a therapeutic effect on the excitation-inhibition balance of the hippocampus.
Study NCT01175590 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle
Description: Vehicle of Besivance administered to affected eye for 7 days
Study NCT00634465 — intervention group
Intervention type: DEVICE
Intervention: RSA Beads
Description: Radiostereometric Analysis, or RSA, is an accurate in vivo measurement technique using two simultaneous radiographs. It provides researchers with three dimensional motion analyses to look not only at routine flexion/extension, but also other rotational and translational changes
Study NCT04251624 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Goal Management Therapy
Description: A cognitive training program aimed at improving cognitive deficits such as in memory, attention, learning, and executive functioning.
Study NCT04251624 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Psychosocial Education
Description: A group therapy program focusing on brain function, neuroplasticity, and lifestyle interventions.
Study NCT01674985 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Microtransplantation
Description: Infusion of G-CSF mobilized HLA-mismatched peripheral blood stem cells (G-PBSC)
Study NCT01489761 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: percutaneous coronary intervention
Description: drug eluting stent implantation
Study NCT01489761 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: percutaneous coronary intervention
Description: drug eluting stent implantation
Study NCT02072694 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 75 grams of glucose plus water solution
Description: A solution composed by 75 grams of glucose and water at ambient temperature is administered to each volunteer, being of the with obesity group or the without obesity group, as follow:~* 300 mL final volume of the solution.~* Time of oral ingestion inferior than 2 minutes.~* 30 minutes before the radiopharmaceutical injection.~* 12 hours fasting minimum.
Study NCT02072694 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: 75 grams of glucose plus water solution
Description: A solution composed by 75 grams of glucose and water at ambient temperature is administered to each volunteer, being of the with obesity group or the without obesity group, as follow:~* 300 mL final volume of the solution.~* Time of oral ingestion inferior than 2 minutes.~* 30 minutes before the radiopharmaceutical injection.~* 12 hours fasting minimum.
Study NCT02072694 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pure water
Description: Pure water at ambient temperature is administered to each volunteer, being of the with obesity group or the without obesity group, as follow:~* 300 mL final volume of the solution.~* Time of oral ingestion inferior than 2 minutes.~* 30 minutes before the radiopharmaceutical injection.~* 12 hours fasting minimum.
Study NCT02072694 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Pure water
Description: Pure water at ambient temperature is administered to each volunteer, being of the with obesity group or the without obesity group, as follow:~* 300 mL final volume of the solution.~* Time of oral ingestion inferior than 2 minutes.~* 30 minutes before the radiopharmaceutical injection.~* 12 hours fasting minimum.
Study NCT00755963 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: maltodextrin
Study NCT01343836 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Autologous Tenocyte Implantation
Description: Intratendinous ATI (autologous tenocyte injection) with eccentric exercises
Study NCT01343836 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: Intratendinous saline injection with eccentric exercises
Study NCT00617617 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Prevastein HC®
Description: Experimental Group - Participants in the experimental group will consume an isoflavones supplement in the form of Prevastein HC®, which will deliver 80 mgs (40 mg/dose) biologically active isoflavones.
Study NCT00617617 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Control Group - Control Group participants will receive an identical placebo.
Study NCT01469091 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Smoking intervention.
Description: Nicotine replacement therapy and meetings with nurse specialized in smoking intervention.
Study NCT00432211 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Avotermin
Description: Complete Excision:- On Day 0,Following wound closure the two outer segments of the wound will receive either Juvista or placebo.100µl of vehicle containing 200ng of Juvista will be injected per linear centimetre into both margins of one segment of the wound,and 100µl of vehicle alone (placebo) will be injected per linear centimetre into the other segment of the wound. There will be a central area (at least 3cm) of untreated wound between the two segments.The treatments will be re-administered to each wound segment (A and B) 24 hours after the first administration.~Staged Excision On Day 0, the two end segments of the scar will be excised.Following wound closure each subject will receive 100µl of vehicle containing 200ng of Juvista per linear centimetre intradermally into one wound, and 100µl of vehicle alone (placebo) per linear centimetre into the other wound.The trial treatments will be re-administered to each wound 24 hours after the first administration.
Study NCT00987753 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: L-377202
Description: For each cycle, L-377202 will be administered as a 30-minute infusion every 3 weeks. The starting dose will be 20 mg/m2/week. Doses will be doubled until a patient experiences a greater than or equal to Grade 2 toxicity.
Study NCT00719849 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: anti-thymocyte globulin
Description: 30mg/Kg Days -6 to -4
Study NCT00719849 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide
Description: 50 mg/Kg Day -6
Study NCT00719849 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclosporine
Description: Patients will receive cyclosporine A (CSA) therapy beginning on Day -3 maintaining a trough level between 250 and 500 ng/mL. For adults the initial dose will be 2.5 mg/kg IV over 1 hour every 12 hours. For children \< 40 kg the initial dose will be 2.5 mg/kg IV over 1 hour every 8 hours.
Study NCT00719849 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fludarabine phosphate
Description: 40mg/m2 Days -6 to -2
Study NCT00719849 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mycophenolate mofetil
Description: 1 gram every 8 hours for patients who are ≥ 40 kg. Pediatric patients (\<40 kilograms) will receive MMF at the dose of 15 mg/kg/dose every 8 hours. Stop MMF at Day +30 or 7 days after engraftment, whichever day is later, if no acute GVHD.
Study NCT00719849 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: umbilical cord blood transplantation
Description: Single or double unit umbilical cord blood transplant
Study NCT00719849 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: total body irradiation
Description: 200 cGy Day -1
Study NCT03806374 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketamine
Description: ketamine
Study NCT03806374 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol
Description: propofol
Study NCT03806374 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fentanyl
Description: fentanyl
Study NCT03806374 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cisatracurium
Description: cisatracurium
Study NCT03806374 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lidocaine
Description: lidocaine
Study NCT04590066 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Flu shot text messages
Description: Participants will receive text messages per descriptions listed in the arms.
Study NCT00763438 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sertindole
Description: Flexible dose
Study NCT02190474 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness Group
Description: Participants will attend weekly 1-2-hour group sessions (of 6-8 persons) led by a trained expert based on the working MBSR protocol. The weekly sessions will be scheduled in a time mutually convenient for participants and their parent/guardian that will accompany them to each group session. The MBSR group sessions will take place at the Yale School of Medicine.
Study NCT00599521 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adapalene lotion 0.1%
Description: Adapalene, 0.1% will be applied topically to the face, once a day, for 12 weeks
Study NCT00599521 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Adapalene Lotion Vehicle
Description: Vehicle will be applied topically to the face, once a day, for 12 weeks
Study NCT01080443 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mycophenolate Mofetil Capsule 250 mg
Description: Subjects will be administered either Test Product or Reference Product with 240 mL of water according to randomization schedule
Study NCT01080443 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mycophenolate Mofetil Capsule 250 mg
Description: Subjects will be administered either Test Product or Reference Product with 240 mL of water according to randomization schedule
Study NCT02841813 — intervention group
Intervention type: OTHER
Intervention: No intervention
Description: No intervention
Study NCT03512860 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: E4/DRSP
Description: Administered as specified in the treatment arm.
Study NCT03512860 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VAL
Description: Administered as specified in the treatment arm.
Study NCT03889067 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Salmonella Typhi challenge
Description: The challenge agents will be delivered in 30 ml of sodium bicarbonate solution, preceded by 120 ml of solution of sodium bicarbonate to neutralise gastric acid.
Study NCT02585934 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RVT-101
Description: once daily, oral, 35 mg tablets
Study NCT02585934 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: once daily, oral, pill manufactured to match RVT-101 35 mg tablet
Study NCT03686449 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Non-cultured Autologous Keratinocyte Suspension
Description: New method for treatment of post-burn raw area
Study NCT03686449 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Adipose-Derived Stem cell-Keratinocyte Suspension
Description: New method for treatment of post-burn raw area
Study NCT03686449 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Split skin graft
Description: Traditional method for treatment of post-burn raw area
Study NCT00005727 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Intervention
Description: Classroom-based nutrition education curriculum designed for individuals with low literacy skills.
Study NCT00005727 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intervention
Description: Classroom-based nutrition education curriculum designed for individuals with low literacy skills.
Study NCT00746018 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: LigaSure vessel sealing system
Description: The investigators intend to enroll a total of 60 patients planned to undergo a total hysterectomy and bilateral salpingo-oophorectomy. There will be two techniques compared in this protocol. The first 30 patients will have the right tube removed with one application of the LigaSure. The LigaSure will be placed and the most proximal portion of the right fallopian tube adjacent to the uterine cornua and will be used to coagulate and cut the tube. The next 30 patients will have the tube ligated in the same fashion as group A however an additional step will be added once the fallopian tube has been removed. The LigaSure will be used to cauterize the remaining medial tissue on the cornua region of the uterus.
Study NCT02149329 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Discontinuation of imipenem-cilastatin or meropenem
Description: Discontinuation of imipenem-cilastatin or meropenem after 3x24 hours irrespective of presence of fever.
Study NCT03967496 — intervention group
Intervention type: PROCEDURE
Intervention: Types of Anesthesia
Description: General Anesthesia includes: Inhalational anesthesia and total intravenous anesthesia.~Regional blocks includes: Spinal Anesthesia, Epidural Anesthesia, Plexus Block, Peripheral Nerve Block,... etc Monitored Anesthesia Care: No anesthetic administered but care given for hemodynamic and blood sugar control intraoperatively.
Study NCT03967496 — intervention group
Intervention type: PROCEDURE
Intervention: Access of Surgery
Description: Type of surgical access
Study NCT03967496 — intervention group
Intervention type: OTHER
Intervention: Comorbidities
Description: A patient may have more than one comorbidity